In the Spotlight...
Drilling dendritic cell activation- Engineering interfacial mechano-biochemical cues for enhanced immunotherapy
Adoptive cell transfer therapy with ex vivo primed peripheral lymphocytes in combination with chemotherapy in locally advanced or metastatic triple-negative breast cancer: the ImmunoBreast phase Ib clinical trial
mRNA engineering of allogeneic mesenchymal stem cells enables coordinated delivery of T cell engagers and immunotherapeutic cues
Prostaglandin E(2)-EP2/EP4 signaling induces the tumor-infiltrating Treg phenotype for tumor growth
Previous Digests
The downside of checkpoint blockade: a loss of stem-like T cells
December 10, 2025
T cells that maintain a stem-like state play a role in replenishing immune responses long-term, but how these cells are shaped and maintained in the context of antitumor immunity is not fully understood. To investigate this question, Hor et...
IL-9-powered CAR-T for improved solid tumor responses
December 3, 2025
Overcoming immunosuppression in the tumor microenvironment (TME) is a major challenge in CAR T cell research to improve therapeutic efficacy towards solid tumors. To address some of the CAR-T functionality challenges, Castelli et al. engineered CAR T cells with...
MiTEs turn TAM suppression into T cell synergy
November 26, 2025
Inhibition or reprogramming of tumor-associated macrophages (TAMs) has great potential to improve the tumor immune environment, but has, so far, shown limited clinical efficacy. To improve macrophage-targeted therapies, von Locquenghien, Zwicky, Cie, et al. described their dual TAM- and...
Watch ACIR in action
In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.
Watch the 3-minute video explaining ACIR's mission and goal:
In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.
Watch the 6-minute segment on the story behind your favorite digest here:
About ACIR
ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.
Ute Burkhardt
Ed Fritsch
Lauren Hitchings
Gaelle Llambi
Maartje Wouters
Alex Najibi
Katherine J. Turner
Stan Wolf
Paula Hochman
Shishir Pant
Nathan Suek
Morgan Janes
TESTIMONIALS
I'm a big fan of ACIR. I enjoy their weekly newsletters with clear, concise, and insightful summaries, complemented by excellent images. I've even used the images in some of my presentations to explain complex cancer immunotherapy findings. In our rapidly evolving field, their reliable and well-curated updates are invaluable.
Richard W. Vague Professor in Immunotherapy; Professor of PL&M; Director, Center for Cellular Immunotherapies; Director, Parker Institute for Cancer Immunotherapy; University of Pennsylvania Perelman School of Medicine. (Supporter since 2025).
Current Sponsors
